Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liu, Chih-Ying | en_US |
dc.contributor.author | Li, Xin | en_US |
dc.contributor.author | Chen, Wen-Yih | en_US |
dc.contributor.author | Chang, Li-Chiao | en_US |
dc.contributor.author | Chen, Yi-Fan | en_US |
dc.contributor.author | Chen, Hsin-Lung | en_US |
dc.contributor.author | Sun, Ya-Sen | en_US |
dc.contributor.author | Lai, Hsiu-Yun | en_US |
dc.contributor.author | Huang, E-Wen | en_US |
dc.date.accessioned | 2014-12-08T15:36:58Z | - |
dc.date.available | 2014-12-08T15:36:58Z | - |
dc.date.issued | 2014-09-30 | en_US |
dc.identifier.issn | 0743-7463 | en_US |
dc.identifier.uri | http://dx.doi.org/10.1021/1a501689d | en_US |
dc.identifier.uri | http://hdl.handle.net/11536/25368 | - |
dc.description.abstract | The structures of C- and N-terminally monoPEGylated human parathyroid hormone fragment hPTH(1-34) as well as their unmodified counterparts, poly(ethylene glycol) (PEG) and hPTH(1-34), have been studied by small-angle neutron scattering (SANS). The scattering results show that free hPTH(1-34) in 100 mM phosphate buffer (pH 7.4) aggregates into clusters. After conjugation with PEG, the PEG-peptide conjugates self-assemble into a supramolecular core-shell structure with a cylindrical shape. The PEG chains form a shell around the hPTH(1-34) core to shield hPTH(1-34) from the solvent. The detailed structural information on the self-assembled structures is extracted from SANS using a model of the cylindrical core with a shell of Gaussian chains attached to the core surface. On the basis of the data, because of the charge-dipole interactions between the conjugated PEG chain and the peptide, the conjugated PEG chain forms a more collapsed conformation compared to free PEG. Moreover, the size of the self-assembled structures formed by the C-terminally monoPEGylated hPTH(1-34) is about 3 times larger than that of the N-terminally monoPEGylated hPTH(1-34). The different aggregation numbers of the self-assembled structures, triggered by different PEGylation sites, are reported. These size discrepancies because of different PEGylation sites could potentially affect the pharmacokinetics of the hPTH(1-34) drug. | en_US |
dc.language.iso | en_US | en_US |
dc.title | PEGylation Site-Dependent Structural Heterogeneity Study of MonoPEGylated Human Parathyroid Hormone Fragment hPTH(1-34) | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1021/1a501689d | en_US |
dc.identifier.journal | LANGMUIR | en_US |
dc.citation.volume | 30 | en_US |
dc.citation.issue | 38 | en_US |
dc.citation.spage | 11421 | en_US |
dc.citation.epage | 11427 | en_US |
dc.contributor.department | 材料科學與工程學系 | zh_TW |
dc.contributor.department | Department of Materials Science and Engineering | en_US |
dc.identifier.wosnumber | WOS:000342607000020 | - |
dc.citation.woscount | 0 | - |
Appears in Collections: | Articles |